#Dixon key beneficiary of GOI PLI scheme
Through its subsidiary Padget electronics, Dixon made 2 applications for phones costing < 15000 ,70% India mobile mkt share
Incentive of 4 to 6% under PLI subject to a cap
Total investment 200crs ,50 cr/yr till 2025 #dixontechnologies
Post expansion revenue share of mobiles to jump to 44 from 12% currently
Ramp up capacity from 3 mn today to 15-16 mn over next few yrs ,aim for revenue 28-30000 crs over next 5 yrs
In talks 3 large players
Set top boxes, delivered 5.2 lakh to jio,dish,Citi
Order book 0.3mn/mon
Dixon is both OEM Player & ODM ( original design manufacturer)
Expanding capacities in Android & Linux TV ,semi automatic and top load washing machines
Current capacity 4 mn TV sets ,30%LED Mkt,acquired new customers Samsung,Nokia,Ramos capacity to 5.5 mn #Nifty#stocks
Washing machine > 100 models in 6 to 10 kg category, launch semi automatic 11 kg ,electronic panel model ,expand top loading model capacity at Tirupati
Largest ODM player in lighting with 215 mn capacity for LED bulbs
Doubled capacity for smart bulbs & batons #amberenterprises
#dixon Indias 2nd largest contract mftrer for consumer electronics
- Foray into ICT hardware eg.laptop,desktop,tablet,server through factory in South India
- 87% laptop, 63% tablet imported from China
- Await GOI PLI for ICT
-11 mftg units 5 UP ,4 Dehradun,2 Tirupati #stocks
Strong demand & order book from existing customers,new customer acquisition to enable 40% growth in revenue,profits in Fy21-22
- ventured into set top box,Medical devices (PCR analyzer for covid ,ICMR Apprvd)
- plan foray refrigerator 0.7 mn units on direct cool side by Fy22-23
• • •
Missing some Tweet in this thread? You can try to
force a refresh
@IndianEnergyXch
Transformation drivers 1) Decarbonization - use of solar & wind ,RE (renewable energy) 2) Decentralisation - RE a threat to centralized energy productn 3) Digitization 4) Democratization- peer 2 peer energy trading
Changing energy mix 2020/ 2022 /2030 % of contribution
Thermal 62 /53 /35
Wind 10 /12 /17
Solar 9 / 20/ 36
Hydro 12 / 10 /8
Electricity value chain 4 parts
Generation - Transmission - Distribution - Consumption
Power sector construct
Long term 90%
Short term 10%
Power markets in developed countries are in range 30 - 80% of total power demand ,India 5%
Share of exchange in total generation
2016 - 2.9 %
2021 - 5.2%
Share of ST market in total generation
2016 - 9.9%
2021 - 10.3%
Exchange mkt & ST MKT as % of total gen
2016 29.9
2021 50.2
@JubilantLifeSci
Q2fy21 Revenue up 4.8% yoy to 2347.9 crs led by traction in CMO/Generics in Pharma & Life sciences in LSI segment
- Radiopharma business impacted by Covid & launch of macroaggregated Albumin (MAA) by competitor Curium(jubilant was sole player) #pharma#Nifty
MAA business witnessed price & mkt share erosion
-DTPA business impacted by decrease in ventilation scan due to covid
-Generic business growth led by traction existing products,launch of Remdesivir
-JLS to launch Remdesivir in 70 countries, exported API to US & injs in India
Radiopharma 90% & allergy business 100% precovid levels
-Partnership with SOFIE Biosciences in molecular theranostics
- JLS to double DDDS capacity by Fy22
- LSI business speciality declined 2% & nutritional grew 11% led by VIT D exports to EU while ethyl acetate muted growth
@GranulesIndia
Q2fy21
Revenue up 22.7% to 858 crs
Formulations up 22.4% yoy 430 crs
API up 17% to 255
PFI up 32.6% to 173 crs
Vizag unit V commissioned for API ,oncology segment,
Company plans gradual shift from commoditized API to more complex drugs/ Formulations #stocks
Company expects to commission MUPS block by Q3fy22
- Revenue contribution of core mols dropped to 70 from 80-85% end of Fy20
- #granules has 32 ANDA approved ,expect to launch 6 of these in Fy21
- Revised PAT guidance to 30% post Fy21 from 25% earlier #StockMarket#Nifty
Company plans 7-9 product filings/year, atleast 5 for the US market
- Top 5 mols contributed 70%
- Capex guidance of 3.5 to 4 bn for fy21 & 3bn for Fy22
- Relaunch Metformin 750 mg in US over next year
- EU sales 23 % expected to reach 28% by Fy23, US sales to decline to 43%
Q2 went well for Room AC industry,uptick retail demand, pent up demand
Overall electronic & consumer durables witnessed a good quarter
Inventory levels back to normal
Anticipate better H2fy21 #stock#StocksToWatch#Nifty#sensex
GOI banned import of refrigerant fill ACs, approx 30% of fully built RACs were imported mkt size 4000 crs , atmanirbhar bharat initiative,oppurtunity for domestic RAC players
Not easy for OEMs to import non-refrigerant fill ACs,unpack,gas fill test,negates cost advantage
#amberenterprises completed QIP 400 cr in Q2fy21, money used for debt repayment,capex,WC ,acquire additional 20% stake in Sidwal,company ready to grab mkt share in RAC
China plus 1 unfolding,global MNC enquiring about RAC & components
Amber started export of components to US
Revenue 933 vs 857 mn yoy, growth 9%
Ebidta up 23%, 254 vs 207 mn yoy
PAT 123 vs 63 mn yoy
Capital reduction exercise complete, shares relisted with FV 5
Project delivery delays due to challenges of remote working #subex#telecom#IOT#nifty
Business front,telcos in Africa,EU tightening their purses,however longterm investment & exploration in 5G,Iot progressing well
IoT security side resumption of business talks stuck post March
Focus on Digital trust,Suresh Chintada new CTO
Digital trust lab to look at new tech like post quantum cryptography, homomorphic encryption, Blockchain
Tech mahindra deal to cooperate in Blockchain,to cover used spaces around digital trust area with our blocking solutions around their platform @TechMahindraIES
@GranulesIndia earnings call transcript Q2fy21
No longer a 5 product company
22 launched products
PAT growth up 80% H1fy21 compared to H1fy20,due to fast approval of filed ANDAs,rapid scale up production
Ebidta,PAT > Rev growth- better product mix,sales,op efficiency #Stocks
32 approved ANDAs(6 yet to launch),13 waiting for approval
Expect 1 MUPS tech based ANDA in Q3 or Q4
Construction MUPS block on track,commercialize Q3fy22
High vol MUPS products & APIs next major driver
Q1fy21 recall of $2 mn tabs Metformin 750mg,this Q 1mn reversed into books
Covid expense 19.3 crs in H1fy21
Rev Q1fy20/21 858/700 cr up23% yoy
Gross margin moved 48.6 to 57.9% YoY thru new launches,increased finished dosages,product rationalization in PFI & Finished dosages
PAT 164 vs 96 crs,up 71% yoy #Stocks#pharma#Nifty#sensex